Glycerin Liquid Laxative Enema (kaisalilu)

Description

The product is identified by the SPL code 34089-3. No specific description details are provided in the text.

Uses and Indications

This drug is indicated for the relief of rectal discomfort and burning sensations associated with its use.

There are no teratogenic or nonteratogenic effects associated with this product.

Dosage and Administration

For adults and children aged 12 years and older, the recommended dosage is one bottle administered once daily. For children aged 6 to under 12 years, the dosage is reduced to half a bottle, also administered once daily.

For children under 6 years of age, it is advised to consult a physician for appropriate dosing recommendations.

The route of administration involves removing the top of the bottle, which is coated with grease. The bottle should then be slowly inserted into the anus, followed by the gentle squeezing of the liquid into the rectum.

Contraindications

Use is contraindicated in patients who are pregnant or breastfeeding. Additionally, it is advised to consult a healthcare professional prior to use.

Warnings and Precautions

The use of laxative products requires careful consideration of specific warnings and precautions to ensure patient safety.

Healthcare professionals should advise patients against the use of laxative products in the presence of abdominal pain, nausea, or vomiting unless specifically directed by a physician. Additionally, if a patient experiences a sudden change in bowel habits that persists for two weeks, it is imperative to consult a healthcare provider prior to initiating laxative therapy.

Laxative products are not intended for use beyond one week unless directed by a healthcare professional. Prolonged use may lead to complications and should be monitored closely. Patients should be informed that rectal bleeding or an inability to have a bowel movement following the use of a laxative may signify a serious underlying condition. In such cases, it is crucial to discontinue use immediately and seek medical advice.

Patients may experience rectal discomfort or a burning sensation during use, which should be communicated to them as a potential side effect. It is important to emphasize that these products are for rectal use only.

In the event of accidental ingestion, patients should be instructed to contact a healthcare provider or a poison control center without delay. Furthermore, if rectal bleeding occurs, patients must stop using the product and consult a physician for further evaluation and management.

Side Effects

Patients may experience various adverse reactions associated with the use of laxative products. Commonly reported reactions include rectal discomfort and a burning sensation. These symptoms may vary in intensity among individuals.

Serious adverse reactions necessitate immediate medical attention. Patients should discontinue use and consult a doctor if they experience rectal bleeding or if there is a failure to have a bowel movement after using the laxative, as these may indicate a serious underlying condition.

It is important to note that laxative products should not be used in the presence of abdominal pain, nausea, or vomiting unless directed by a healthcare professional. Additionally, patients are advised to seek medical advice if they notice a sudden change in bowel habits that persists for more than two weeks. Laxative use should be limited to a duration of one week unless otherwise directed by a doctor to avoid potential complications.

Drug Interactions

No specific drug interactions have been identified in the available data. Additionally, there are no reported interactions with laboratory tests. Therefore, no dosage adjustments or monitoring recommendations are necessary based on the current information.

Packaging & NDC

Below are the non-prescription pack sizes of Glycerin Liquid Laxative Enema (kaisalilu) (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 12 years and older are recommended to use 1 bottle once daily. For children aged 6 to under 12 years, the dosage is reduced to ½ bottle once daily. For children under 6 years, it is advised to consult a doctor before use.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should not use this medication. The potential risks associated with the use of this drug during pregnancy and lactation have not been established, and its safety profile in these populations remains unclear. Healthcare professionals are advised to consider alternative treatments for women who are pregnant or nursing to avoid any potential adverse effects on fetal outcomes or infant health.

Lactation

Lactating mothers are advised against the use of this medication. It is important for lactating mothers to consult a healthcare professional prior to use, especially if they are breastfeeding. The safety of this medication in breastfed infants has not been established, and potential risks cannot be ruled out.

Renal Impairment

There is no information available regarding renal impairment, dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to patients with renal impairment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise from an overdose. Symptoms can vary widely depending on the substance involved and the individual patient's response.

In the event of an overdose, the following management procedures should be considered:

1. Assessment: Conduct a thorough assessment of the patient's clinical status, including vital signs and level of consciousness.

2. Supportive Care: Provide supportive care as needed, which may include airway management, oxygen supplementation, and intravenous fluids.

3. Consultation: Engage with a poison control center or a medical toxicologist for guidance on specific interventions and antidotes, if applicable.

4. Documentation: Document all findings, interventions, and the patient's response to treatment meticulously.

Healthcare professionals should remain vigilant and prepared to implement appropriate measures in the event of an overdose, even in the absence of specific overdosage data.

Nonclinical Toxicology

The use of this product is contraindicated in pregnant or breastfeeding individuals. Consultation with a healthcare professional is advised prior to use.

In terms of non-teratogenic effects, the product may induce rectal discomfort or a burning sensation.

No specific information is available regarding carcinogenicity, mutagenicity, or impairment of fertility. Additionally, there is no detailed data provided concerning animal pharmacology and toxicology.

Postmarketing Experience

Postmarketing experience has identified reports of rectal discomfort and a burning sensation associated with the use of this product. These events have been documented through voluntary reporting and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to contact their doctor or a poison control center immediately in the event of accidental ingestion of the medication. It is crucial for patients to understand the importance of prompt action in such situations to ensure their safety.

Additionally, healthcare providers should emphasize the need for patients who are pregnant or breastfeeding to consult with a health professional before using the medication. This discussion is essential to assess any potential risks and to ensure the well-being of both the patient and the child.

Storage and Handling

The product is supplied in a configuration that ensures optimal usability. It should be stored at room temperature to maintain its efficacy. It is essential to keep the product out of reach of children to prevent accidental ingestion. Once opened, the product must be discarded to ensure safety and effectiveness.

Additional Clinical Information

The route of administration for the medication is rectal. For adults and children aged 12 years and older, the recommended dosage is one bottle once daily. For children aged 6 to under 12 years, the dosage is half a bottle once daily. For children under 6 years, it is advised to consult a doctor before use.

Clinicians should counsel patients to keep the medication out of reach of children. In the event of accidental ingestion, patients should contact a doctor or a poison control center immediately. Patients are also advised to discontinue use and consult a doctor if they experience rectal bleeding.

Drug Information (PDF)

This file contains official product information for Glycerin Liquid Laxative Enema (kaisalilu), including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)